The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.
 
Ana Veneziani
No Relationships to Disclose
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Husam Alqaisi
No Relationships to Disclose
 
Gita Bhat
No Relationships to Disclose
 
Ilaria Colombo
Employment - Medacta (I); Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Honoraria - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Consulting or Advisory Role - MSD Oncology
Research Funding - Bayer (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst)
Travel, Accommodations, Expenses - Tesaro
 
Eduardo Gonzalez
No Relationships to Disclose
 
Sara Newton
No Relationships to Disclose
 
Anthony Msan
No Relationships to Disclose
 
Judy Quintos
No Relationships to Disclose
 
Janelle Ramsahai
No Relationships to Disclose
 
Robert C. Grant
No Relationships to Disclose
 
Neesha C. Dhani
Honoraria - AstraZeneca
 
Lisa Wang
No Relationships to Disclose
 
Valerie Bowering
No Relationships to Disclose
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research